A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP) (OPTIMA-2)
Phase 3 Evaluation of the Safety, Pharmacokinetics, and Efficacy of Garetosmab (Anti-Activin A Monoclonal Antibody) in Children and Adolescents With Fibrodysplasia Ossificans Progressiva
This study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on children and adolescent participants with FOP. For United States: Ages 4 to less than 18 years; for non-US sites only: Ages 2 to less than 18 years.
The aim of the study is to see how safe, tolerable, and effective the study drug is.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
研究概览
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Clinical Trials Administrator
- 电话号码:844-734-6643
- 邮箱:clinicaltrials@regeneron.com
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
-
For USA participants, age criteria are 4 to < 18 years old, at the time of the administration of the first dose of study intervention. Non-USA participants age criteria are 2 to < 18 years old
-
Must have a confirmation of FOP diagnosis, as described in the protocol
-
At the time of enrollment, participants must weight:
- Cohort 1: more than 30 kg (or 66.1 pounds)
- Cohort 2: more than 30 kg (or 66.1 pounds)
- Cohort 3: less than or equal to 30 kg (or 66.1 pounds)
Key Exclusion Criteria:
- Cumulative Analog Joint Involvement Scale (CAJIS) score > 19 at the time of screening
- Participant has significant concomitant illness or history of significant illness, as described in the protocol
- Previous history or diagnosis of cancer
- Ongoing significant viral or bacterial illness, within 2 weeks of the first study drug administration
- History of severe respiratory compromise requiring oxygen, respiratory support
- Known history of cerebral vascular malformation
- Participants with a history of severe, non-traumatic bleeding requiring transfusion or hospitalization for hemodynamic compromise
- Participants with a known pre-existing medical history of a bleeding diathesis, as described in the protocol
- Participants who have used palovarotene in the last 30 days or within 5 half-lives of the therapy, whichever is longer from the day of randomization
NOTE: Other Protocol-defined Inclusion/Exclusion Criteria Apply
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Cohort 1: Adolescents
Participants aged 12 - 18 years old |
Administered per the protocol
其他名称:
|
|
实验性的:Cohort 2: Children
Children who are 4 to 12 years old (for non-US sites only 2 to 12 years old) |
Administered per the protocol
其他名称:
|
|
实验性的:Cohort 3: Children and Adolescents
Participants and Children aged 4 to 18 years old (for non-US sites only 2 to 18 years old) |
Administered per the protocol
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Severity of TEAEs
大体时间:Baseline to week 56
|
Baseline to week 56
|
|
Concentrations of functional garetosmab in serum
大体时间:Through week 56
|
Through week 56
|
|
Occurrence of Treatment-Emergent Adverse Event (TEAEs)
大体时间:Baseline to week 56
|
Baseline to week 56
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of new HO lesions
大体时间:At week 28 and week 56
|
At week 28 and week 56
|
|
|
Occurrence of new HO lesions
大体时间:At week 28 and week 56
|
At week 28 and week 56
|
|
|
Number of clinician-assessed flare-ups
大体时间:Through week 28 and week 56
|
Through week 28 and week 56
|
|
|
Occurrence of clinician-assessed flare-ups
大体时间:Through week 28 and week 56
|
Through week 28 and week 56
|
|
|
Characteristics of menstrual cycles for female participants who reached menarche
大体时间:Over 28 weeks and 56 weeks
|
Over 28 weeks and 56 weeks
|
|
|
Concentrations of total activin A in serum
大体时间:Through week 56
|
Through week 56
|
|
|
Occurence of Anti-Drug Antibody (ADA) to garetosmab
大体时间:Through week 56
|
Through week 56
|
|
|
Magnitude of ADA to garetosmab
大体时间:Through week 56
|
Through week 56
|
|
|
Change from baseline in hearing function as assessed by audiometry
大体时间:At week 28 and week 56
|
At week 28 and week 56
|
|
|
Total volume of new Heterotopic Ossification (HO) lesions
大体时间:At week 28 and week 56
|
At week 28 and week 56
|
|
|
Change from baseline in total volume of HO lesions
大体时间:At week 28 and week 56
|
At week 28 and week 56
|
|
|
Change from baseline in Tanner puberty scale
大体时间:At week 28 and week 56
|
Tanner puberty scale or stages: Staging of sexual development is graded on a 5-point ordinal scale ranging from 1 (prepubertal) to 5 (adultlike) for female breast development, male external genitals, and pubic hair |
At week 28 and week 56
|
|
Height-for-age Z-Scores according to the World Health Organization (WHO) Growth Reference Data for Children
大体时间:Through week 56
|
Participants 5-19 years of age Z-score represents standardized measure of how far an individual deviated from study cohort average at baseline. A higher Z-score reflects better performance. |
Through week 56
|
|
Change from baseline in knee height
大体时间:At week 28 and week 56
|
At week 28 and week 56
|
|
|
Change from baseline in Pediatric Quality of Life inventory (PedsQL) scores
大体时间:At week 28 and week 56
|
Age-appropriate PedsQL Generic Core Scales will be used to measure HRQoL in children and adolescents. Response options include 5-point Likert scale (or 3-point Likert scale for the young children self-report) for each item asking about experience within the past week. Global scores are transformed to a 0 to 100 scale with higher scores indicating better quality of life. |
At week 28 and week 56
|
|
Acceptability or tolerability assessment via exit interview
大体时间:Up to week 52
|
Each interview will be conducted by trained external interviewers following a semi-structured interview guide of questions for the participants about their overall experience in the trial. |
Up to week 52
|
合作者和调查者
调查人员
- 研究主任:Clinical Trial Management、Regeneron Pharmaceuticals
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- R2477-FOP-2413
- 2024-518415-19-01 (克蒂斯)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
IPD 共享时间框架
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD 共享访问标准
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 分析代码
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.